Skip Navigation

Susana M. Campos, MD, MPH


Medical Oncology

Make an Appointment
Watch Video

Physician

  • Institute Physician
  • Assistant Professor of Medicine, Harvard Medical School

Centers/Programs

Clinical Interests

  • Breast oncology
  • Gynecologic oncology

Contact Information

  • Appointments(617) 632-2175
  • Office Phone Number617-632-5269
  • Fax617-632-3479

Bio

Dr. Campos received her MD from Georgetown University in 1992, and then completed residency training at Georgetown Medical Center. Between 1995 and 1998, she completed a fellowship in hematology-oncology at Brigham and Women's Hospital, in Boston, and in 2000 received her MPH from Harvard Medical School. She serves on committees for the American Society of Clinical Oncology, the Gynecological Oncology Group, and the National Comprehensive Cancer Network. She is board-certified in internal medicine, oncology, and hematology.

Board Certification:

  • Hematology, 2003
  • Internal Medicine, 1997
  • Medical Oncology, 1999

Fellowship:

  • Brigham and Women's Hospital
  • Dana-Farber/Partners CancerCare, Hematology/Oncology

Residency:

  • Georgetown University Medical Center, Internal Medicine

Medical School:

  • Georgetown University School of Medicine

Research

Novel Therapies in Breast and Gynecological Cancers

Our research interests center on the clinical application of novel therapies - including epidermal growth factor receptor (EGFR) inhibitors, angiogenesis inhibitors, novel cytotoxic therapies, and hormonal agents - in breast and gynecological cancers. The EGFR superfamily is an attractive therapeutic target because it is commonly overexpressed in women's cancers, it regulates vital cellular processes, and it seems to be a negative prognostic indicator. Clinical trials focusing on novel therapies for breast, ovarian, and endometrial cancer are an important area of our research. Past trials have included (1) a comparison of exemestane versus anastrozole in postmenopausal women, (2) the role of D-99 and Herceptin in the management of metastatic breast cancer, (3) the role of CI-1033 given alone in advanced ovarian cancer, and (4) the role of CI-1033 in the management of advanced breast cancer. Current active trials include (1) the role of oral irinotecan in metastatic breast cancer, (2) a phase I trial of DOXIL/ Iressa in patients with gynecological malignancies and metastatic breast cancer, and (3) a retrospective review of newly diagnosed premenopausal women with endometrial cancer. Current projects include the establishment of a research program in endometrial cancer with specific attention to the adjuvant management of high-risk and metastatic disease. We are exploring ideas that include the role of aromatase inhibitors and Cox 2 inhibitors in the management of advanced endometrial cancer, the role of three-drug combinations as adjuvant therapy in the management of endometrial cancer, and the role of anti-VEGF molecules with cytotoxic therapy in advanced gynecological malignancies. Other research interests include the adjuvant management of advanced and poor histological types of endometrial cancer, new agents for metastatic endometrial cancers, and an epidemiological study of young premenopausal women with endometrial cancer.

Koh WJ, Abu-Rustum NR, Bean S, Bradley K, Campos SM, Cho KR, Chon HS, Chu C, Cohn D, Crispens MA, Damast S, Dorigo O, Eifel PJ, Fisher CM, Frederick P, Gaffney DK, George S, Han E, Higgins S, Huh WK, Lurain JR, Mariani A, Mutch D, Nagel C, Nekhlyudov L, Fader AN, Remmenga SW, Reynolds RK, Tillmanns T, Ueda S, Wyse E, Yashar CM, McMillian NR, Scavone JL. Uterine Neoplasms, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2018 Feb; 16(2):170-199.
View in: PubMed

Alabed YZ, Cheng SC, Mudge C, Sakellis C, Van den Abbeele AD, Campos SM, Jacene HA. Surveillance Imaging in Patients With Endometrial Cancer in First Remission. Curr Probl Diagn Radiol. 2018 Sep; 47(5):311-316.
View in: PubMed

Koh WJ, Greer BE, Abu-Rustum NR, Campos SM, Cho KR, Chon HS, Chu C, Cohn D, Crispens MA, Dizon DS, Dorigo O, Eifel PJ, Fisher CM, Frederick P, Gaffney DK, Han E, Higgins S, Huh WK, Lurain JR, Mariani A, Mutch D, Nagel C, Nekhlyudov L, Fader AN, Remmenga SW, Reynolds RK, Tillmanns T, Ueda S, Valea FA, Wyse E, Yashar CM, McMillian N, Scavone J. Vulvar Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017 01; 15(1):92-120.
View in: PubMed

Del Carmen MG, Supko JG, Horick NK, Rauh-Hain JA, Clark RM, Campos SM, Krasner CN, Atkinson T, Birrer MJ. Phase 1 and 2 study of carboplatin and pralatrexate in patients with recurrent, platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer. Cancer. 2016 Nov 15; 122(21):3297-3306.
View in: PubMed

Sloane D, Govindarajulu U, Harrow-Mortelliti J, Barry W, Hsu FI, Hong D, Laidlaw T, Palis R, Legere H, Bunyavanich S, Breslow R, Wesemann D, Barrett N, Brennan P, Chong HJ, Liu A, Fernandez J, Fanning L, Kyin T, Cahill K, Bankova L, Lynch A, Berlin S, Campos S, Fuchs C, Mayer R, Matulonis U, Castells M. Safety, Costs, and Efficacy of Rapid Drug Desensitizations to Chemotherapy and Monoclonal Antibodies. J Allergy Clin Immunol Pract. 2016 May-Jun; 4(3):497-504.
View in: PubMed

Picard M, Pur L, Caiado J, Giavina-Bianchi P, Galvão VR, Berlin ST, Campos SM, Matulonis UA, Castells MC. Risk stratification and skin testing to guide re-exposure in taxane-induced hypersensitivity reactions. J Allergy Clin Immunol. 2016 Apr; 137(4):1154-1164.e12.
View in: PubMed

Koh WJ, Greer BE, Abu-Rustum NR, Apte SM, Campos SM, Cho KR, Chu C, Cohn D, Crispens MA, Dizon DS, Dorigo O, Eifel PJ, Fisher CM, Frederick P, Gaffney DK, George S, Han E, Higgins S, Huh WK, Lurain JR, Mariani A, Mutch D, Fader AN, Remmenga SW, Reynolds RK, Tillmanns T, Valea FA, Yashar CM, McMillian NR, Scavone JL. Uterine Sarcoma, Version 1.2016: Featured Updates to the NCCN Guidelines. J Natl Compr Canc Netw. 2015 Nov; 13(11):1321-31.
View in: PubMed

Matulonis U, Berlin S, Lee H, Whalen C, Obermayer E, Penson R, Liu J, Campos S, Krasner C, Horowitz N. Phase I study of combination of vorinostat, carboplatin, and gemcitabine in women with recurrent, platinum-sensitive epithelial ovarian, fallopian tube, or peritoneal cancer. Cancer Chemother Pharmacol. 2015 Aug; 76(2):417-23.
View in: PubMed

Koh WJ, Greer BE, Abu-Rustum NR, Apte SM, Campos SM, Cho KR, Chu C, Cohn D, Crispens MA, Dorigo O, Eifel PJ, Fisher CM, Frederick P, Gaffney DK, Han E, Huh WK, Lurain JR, Mutch D, Fader AN, Remmenga SW, Reynolds RK, Teng N, Tillmanns T, Valea FA, Yashar CM, McMillian NR, Scavone JL. Cervical Cancer, Version 2.2015. J Natl Compr Canc Netw. 2015 Apr; 13(4):395-404; quiz 404.
View in: PubMed

Worley MJ, Davis M, Berhie SH, Muto MG, Feltmate CM, Berkowitz RS, Horowitz NS, Campos SM. Mucinous differentiation does not impact stage or risk of recurrence among patients with grade 1, endometrioid type, endometrial carcinoma. Gynecol Oncol. 2014 Oct; 135(1):54-7.
View in: PubMed

Campos SM, Brady WE, Moxley KM, O'Cearbhaill RE, Lee PS, DiSilvestro PA, Rotmensch J, Rose PG, Thaker PH, O'Malley DM, Hanjani P, Zuna RE, Hensley ML. A phase II evaluation of pazopanib in the treatment of recurrent or persistent carcinosarcoma of the uterus: a gynecologic oncology group study. Gynecol Oncol. 2014 Jun; 133(3):537-41.
View in: PubMed

Koh WJ, Greer BE, Abu-Rustum NR, Apte SM, Campos SM, Chan J, Cho KR, Cohn D, Crispens MA, Dupont N, Eifel PJ, Fader AN, Fisher CM, Gaffney DK, George S, Han E, Huh WK, Lurain JR, Martin L, Mutch D, Remmenga SW, Reynolds RK, Small W, Teng N, Tillmanns T, Valea FA, McMillian N, Hughes M. Uterine neoplasms, version 1.2014. J Natl Compr Canc Netw. 2014 Feb; 12(2):248-80.
View in: PubMed

Dizon DS, Ambrosio AJ, Feltmate C, Wright AA, Campos SM, Viswanathan A. Pushing the bar in treatment of cervical cancer: what can comprehensive cancer centers do on their own? Gynecol Oncol. 2013 Nov; 131(2):464-6.
View in: PubMed

Koh WJ, Greer BE, Abu-Rustum NR, Apte SM, Campos SM, Chan J, Cho KR, Cohn D, Crispens MA, DuPont N, Eifel PJ, Gaffney DK, Giuntoli RL, Han E, Huh WK, Lurain JR, Martin L, Morgan MA, Mutch D, Remmenga SW, Reynolds RK, Small W, Teng N, Tillmanns T, Valea FA, McMillian NR, Hughes M. Cervical cancer. J Natl Compr Canc Netw. 2013 Mar 01; 11(3):320-43.
View in: PubMed

Rauh-Hain JA, Nitschmann CC, Worley MJ, Bradford LS, Berkowitz RS, Schorge JO, Campos SM, del Carmen MG, Horowitz NS. Platinum resistance after neoadjuvant chemotherapy compared to primary surgery in patients with advanced epithelial ovarian carcinoma. Gynecol Oncol. 2013 Apr; 129(1):63-8.
View in: PubMed

Campos SM, Doverspike L, Spinks M, Jacobson JO. Securing discharge follow-up appointments in a women's cancer program. J Clin Oncol. 2012 Dec; 30(34_suppl):81.
View in: PubMed

Campos SM, Penson RT, Matulonis U, Horowitz NS, Whalen C, Pereira L, Tyburski K, Roche M, Szymonifka J, Berlin S. A phase II trial of Sunitinib malate in recurrent and refractory ovarian, fallopian tube and peritoneal carcinoma. Gynecol Oncol. 2013 Feb; 128(2):215-20.
View in: PubMed

Esselen KM, Rodriguez N, Growdon W, Krasner C, Horowitz NS, Campos S. Patterns of recurrence in advanced epithelial ovarian, fallopian tube and peritoneal cancers treated with intraperitoneal chemotherapy. Gynecol Oncol. 2012 Oct; 127(1):51-4.
View in: PubMed

Matulonis UA, Pereira L, Liu J, Lee H, Lee J, Whalen C, Campos S, Atkinson T, Hill M, Berlin S. Sequential bevacizumab and oral cyclophosphamide for recurrent ovarian cancer. Gynecol Oncol. 2012 Jul; 126(1):41-6.
View in: PubMed

Campos SM, Dizon DS. Antimitotic inhibitors. Hematol Oncol Clin North Am. 2012 Jun; 26(3):607-28, viii-ix.
View in: PubMed

Konstantinopoulos PA, Berlin ST, Campos SM, Matulonis UA, Cannistra SA. Bevacizumab rechallenge after first line maintenance bevacizumab. Gynecol Oncol. 2012 May; 125(2):510-1.
View in: PubMed

Campos SM, Berlin S, Matulonis UA, Muto MG, Pereira L, Mosquera MM, Horowitz N. Young women diagnosed with early-stage ovarian cancer or borderline malignancy of the ovary: a focus on fertility and sexual function. J Psychosoc Oncol. 2012; 30(4):387-401.
View in: PubMed

Parithivel K, Jagannathan JP, Krajewski K, O'Regan K, Quick CM, Ramaiya N, Campos S. Ovarian squamous cell carcinoma arising from mature cystic teratoma. Cancer Imaging. 2011 Jun 15; 11:67-9.
View in: PubMed

Esselen KM, Rodriguez N, Horowitz NS, Campos SM. Patterns of recurrence in advanced epithelial ovarian, fallopian tube, and peritoneal cancers treated with intraperitoneal chemotherapy. J Clin Oncol. 2011 May 20; 29(15_suppl):5072.
View in: PubMed

Viswanathan AN, Szymonifka J, Tanaka C, Berlin ST, Campos SM, Horowitz NS, Lee J, Whalen C, Matulonis U. The use of bevacizumab and concurrent radiation for recurrent gynecologic cancers. J Clin Oncol. 2011 May 20; 29(15_suppl):5101.
View in: PubMed

Partridge EE, Abu-Rustum NR, Campos SM, Fahey PJ, Farmer M, Garcia RL, Giuliano A, Jones HW, Lele SM, Lieberman RW, Massad SL, Morgan MA, Reynolds RK, Rhodes HE, Singh DK, Smith-McCune K, Teng N, Trimble CL, Valea F, Wilczynski S. Cervical cancer screening. J Natl Compr Canc Netw. 2010 Dec; 8(12):1358-86.
View in: PubMed

Greer BE, Koh WJ, Abu-Rustum NR, Apte SM, Campos SM, Chan J, Cho KR, Copeland L, Crispens MA, Dupont N, Eifel PJ, Gaffney DK, Huh WK, Kapp DS, Lurain JR, Martin L, Morgan MA, Morgan RJ, Mutch D, Remmenga SW, Reynolds RK, Small W, Teng N, Valea FA. Cervical cancer. J Natl Compr Canc Netw. 2010 Dec; 8(12):1388-416.
View in: PubMed

Campos SM, Berlin ST, Parker LM, Chen WY, Bunnell CA, Atkinson T, Lee J, Matulonis U, Hirsch MS, Harris L, Krasner CN. Phase I trial of liposomal doxorubicin and ZD1839 in patients with refractory gynecological malignancies or metastatic breast cancer. Int J Clin Oncol. 2010 Aug; 15(4):390-8.
View in: PubMed

Campos SM, Ghosh S. A current review of targeted therapeutics for ovarian cancer. J Oncol. 2010; 2010:149362.
View in: PubMed

Penson RT, Dizon DS, Cannistra SA, Roche MR, Krasner CN, Berlin ST, Horowitz NS, Disilvestro PA, Matulonis UA, Lee H, King MA, Campos SM. Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian tumors. J Clin Oncol. 2010 Jan 01; 28(1):154-9.
View in: PubMed

Matulonis UA, Berlin S, Ivy P, Tyburski K, Krasner C, Zarwan C, Berkenblit A, Campos S, Horowitz N, Cannistra SA, Lee H, Lee J, Roche M, Hill M, Whalen C, Sullivan L, Tran C, Humphreys BD, Penson RT. Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer. J Clin Oncol. 2009 Nov 20; 27(33):5601-6.
View in: PubMed

Mirabeau-Beale KL, Kornblith AB, Penson RT, Lee H, Goodman A, Campos SM, Duska L, Pereira L, Bryan J, Matulonis UA. Comparison of the quality of life of early and advanced stage ovarian cancer survivors. Gynecol Oncol. 2009 Aug; 114(2):353-9.
View in: PubMed

Greer BE, Koh WJ, Abu-Rustum N, Bookman MA, Bristow RE, Campos SM, Cho KR, Copeland L, Crispens MA, Eifel PJ, Huh WK, Jaggernauth W, Kapp DS, Kavanagh JJ, Lurain JR, Morgan M, Morgan RJ, Powell CB, Remmenga SW, Reynolds RK, Alvarez Secord A, Small W, Teng N. Uterine Neoplasms. Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2009 May; 7(5):498-531.
View in: PubMed

Theodoulou M, Batist G, Campos S, Winer E, Welles L, Hudis C. Phase I study of nonpegylated liposomal doxorubicin plus trastuzumab in patients with HER2-positive breast cancer. Clin Breast Cancer. 2009 May; 9(2):101-7.
View in: PubMed

Campos SM, Guastalla JP, Subar M, Abreu P, Winer EP, Cameron DA. A comparative study of exemestane versus anastrozole in patients with postmenopausal breast cancer with visceral metastases. Clin Breast Cancer. 2009 Feb; 9(1):39-44.
View in: PubMed

Burstein HJ, Chen YH, Parker LM, Savoie J, Younger J, Kuter I, Ryan PD, Garber JE, Chen H, Campos SM, Shulman LN, Harris LN, Gelman R, Winer EP. VEGF as a marker for outcome among advanced breast cancer patients receiving anti-VEGF therapy with bevacizumab and vinorelbine chemotherapy. Clin Cancer Res. 2008 Dec 01; 14(23):7871-7.
View in: PubMed

Matulonis UA, Horowitz NS, Campos SM, Lee H, Lee J, Krasner CN, Berlin S, Roche MR, Duska LR, Pereira L, Kendall D, Penson RT. Phase II study of carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer. J Clin Oncol. 2008 Dec 10; 26(35):5761-6.
View in: PubMed

Campos SM. Anti-epidermal growth factor receptor strategies for advanced breast cancer. Cancer Invest. 2008 Oct; 26(8):757-68.
View in: PubMed

Cervantes A, Roselló S, Rodríguez-Braun E, Navarro S, Campos S, Hernández A, García-Granero E. Progress in the multidisciplinary treatment of gastrointestinal cancer and the impact on clinical practice: perioperative management of rectal cancer. Ann Oncol. 2008 Sep; 19 Suppl 7:vii266-72.
View in: PubMed

Castells MC, Tennant NM, Sloane DE, Hsu FI, Barrett NA, Hong DI, Laidlaw TM, Legere HJ, Nallamshetty SN, Palis RI, Rao JJ, Berlin ST, Campos SM, Matulonis UA. Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases. J Allergy Clin Immunol. 2008 Sep; 122(3):574-80.
View in: PubMed

Castells MC, Tennant NM, Sloane DE, Hsu FI, Berlin ST, Campos SM, Matulonis UA. Anaphylactic and anaphylactoid reactions to chemotherapy: outcomes and safety of rapid intravenous and intraperitoneal desensitizations in 413 cases. J Clin Oncol. 2008 May 20; 26(15_suppl):5526.
View in: PubMed

Horowitz NS, Penson RT, Campos SM, Lee J, Kendall DL, Krasner CN, Berlin ST, Roche M, Duska LR, Matulonis UA. Combination carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer. J Clin Oncol. 2008 May 20; 26(15_suppl):5523.
View in: PubMed

Mirabeau-Beale K, Kornblith AB, Penson RT, Lee H, Goodman A, Campos SM, Duska LR, Pereira L, Gibson CD, Matulonis UA. Comparison of the quality of life of early and advanced stage ovarian cancer survivors. J Clin Oncol. 2008 May 20; 26(15_suppl):5528.
View in: PubMed

N.S.Horowitz, R.T.Penson, S.M.Campos, J.Lee, D.L.Kendall, C.N.Krasner, S.T.Berlin, M.Roche, L.R.Duska, U.A.Matulonis. Combination carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer. 2008; 26(ASCO 2008):A: 5523.
View in: PubMed

Partridge EE, Abu-Rustum N, Campos S, Fahey PJ, Greer BE, Lele SM, Lieberman RW, Lipscomb GH, Morgan M, Nava ME, Reynolds RK, Singh DK, Smith-McCune K, Teng N, Trimble CL, Valea F, Wilczynski S. Cervical cancer screening. J Natl Compr Canc Netw. 2008 Jan; 6(1):58-82.
View in: PubMed

K.Mirabeale, A.B.Kornblith, R.T. Penson, H.Lee, A.Goodman, S.M.Campos, L.R.Duska, L.Pereira, C.D.Gibson, U.A.Matulonis. Comparison of the quality of life of early and advanced stage ovarian cancer survivors. 2008; 26(ASCO 2008):A:5528.
View in: PubMed

Greer BE, Koh WJ, Abu-Rustum N, Bookman MA, Bristow RE, Campos S, Cho KR, Copeland L, Eifel P, Huh WK, Jaggernauth W, Kapp DS, Kavanagh J, Lipscomb GH, Lurain JR, Morgan M, Morgan RJ, Powell CB, Remmenga SW, Reynolds RK, Secord AA, Small W, Teng N. Cervical cancer. J Natl Compr Canc Netw. 2008 Jan; 6(1):14-36.
View in: PubMed

M.C.Castells, N.M.Tennant, D.E.Sloane, F.I.Hsu, S.T.Berlin, S.M.Campos, U.A.Matulonis. Anaphylactic and anaphylactoid reactions to chemotherapy: outcomes and safety of rapid intervenous and intraperitoneal desensitizations in 413 cases. 2008; 26(ASCO 2008):A:5526.
View in: PubMed

Krasner CN, McMeekin DS, Chan S, Braly PS, Renshaw FG, Kaye S, Provencher DM, Campos S, Gore ME. A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens. Br J Cancer. 2007 Dec 17; 97(12):1618-24.
View in: PubMed

Cervantes A, Rodríguez-Braun E, Navarro S, Hernández A, Campos S, García-Granero E. Integrative decisions in rectal cancer. Ann Oncol. 2007 Jul; 18 Suppl 9:ix127-31.
View in: PubMed

A.Viswanathan, N.Horick, C.Tanaka, S.Campos, U.Matulonis, R.Berkowitz. Chemotherapy and radiation therapy UPSC. 2007; 25(ASCO 2007):A:5535.
View in: PubMed

S.M.Campos, D.S.Dizon, S.A.Cannistra, M.Roche, C.N.Krasner, S.T.Berlin, N.S.Horowitz, P. DiSilvestro, U.A.Matulonis, R.T.Penson. Safety of maintenance bevacizumab after first-line chemotherapy for advanced ovarin and mullerian cancers. 2007; 25(ASCO 2007):A:5517.
View in: PubMed

Cervantes A, Chirivella I, Rodriguez-Braun E, Campos S, Navarro S, García Granero E. A multimodality approach to localized rectal cancer. Ann Oncol. 2006 Sep; 17 Suppl 10:x129-34.
View in: PubMed

Matulonis UA, Campos S, Krasner CN, Duska LR, Penson RT, Falke R, Roche M, Smith LM, Lee H, Seiden MV. Three sequential chemotherapy doublets for the treatment of newly diagnosed advanced müllerian malignancies: the modified triple doublet regimen. Gynecol Oncol. 2006 Nov; 103(2):575-80.
View in: PubMed

Campos SM, Parker L, Chen W, Bunnell CA, Atkinson T, Lee J, Matulonis UA, Harris LN, Krasner CN. Phase I trial of liposomal doxorubicin and ZD 1839 in patients with refractory gynecological malignancies or metastatic breast cancer. J Clin Oncol. 2006 Jun 20; 24(18_suppl):5085.
View in: PubMed

Penson RT, Cannistra SA, Seiden MV, Krasner CN, Matulonis UA, Horowitz NS, Berlin S, Dizon DS, Lee H, Campos SM. Phase II study of carboplatin, paclitaxel and bevacizumab as first line chemotherapy and consolidation for advanced müllerian tumors. J Clin Oncol. 2006 Jun 20; 24(18_suppl):5020.
View in: PubMed

Greer BE, Koh WJ, Abu-Rustum N, Bookman MA, Bristow RE, Campos S, Cho KR, Copeland L, Eifel P, Jaggernauth W, Jhingran A, Kapp DS, Kavanagh J, Lipscomb GH, Lurain JR, Morgan RJ, Nag S, Partridge EE, Powell CB, Remmenga SW, Reynolds RK, Small W, Soper J, Teng N. Uterine cancers. J Natl Compr Canc Netw. 2006 May; 4(5):438-62.
View in: PubMed

Matulonis UA, Campos S, Duska L, Krasner CN, Atkinson T, Penson RT, Seiden MV, Verrill C, Fuller AF, Goodman A. Phase I/II dose finding study of combination cisplatin and gemcitabine in patients with recurrent cervix cancer. Gynecol Oncol. 2006 Oct; 103(1):160-4.
View in: PubMed

R.T.Penson, S.A.Cannistra, M.V.Seiden, C.N.Krasner, U.A.Matulonis, N.S.Horowitz, S.T.Berlin, D.S.Dizon, H.Lee, S.M.Campos, n.representing members of the Dana-Farber Harvard Cancer Institute. Phase II study of carboplatin, paclitaxel and bevacizumab as first line chemotherapy and consolidation for advanced mullerian tumors. 2006; 24(ASCO 2006):A:5020.
View in: PubMed

S.M.Campos, L.Parker, W.Chen, C.A.Bunnell, T.Atkinson, J.Lee, U.A.Matulonis, L.N.Harris, C.N. Krasner. Phase I trial of liposomal doxorubicin and ZD 1839 in patients with refractoy gynecological malignancies or metastatic breast cancer. 2006; 24(ASCO 2006):A:5085.
View in: PubMed

Campos SM, Duh MS, Lefebvre P, Rosberg J. Benefits associated with an early hemoglobin response to epoetin alfa therapy in the treatment of chemotherapy-related anemia. J Natl Compr Canc Netw. 2005 Nov; 3(6):807-16.
View in: PubMed

Penson RT, Campos SM, Seiden MV, Krasner C, Fuller AF, Goodman A, Roche M, Willman A, Muzikansky A, Matulonis UA. A phase II study of fixed dose rate gemcitabine in patients with relapsed müllerian tumors. Int J Gynecol Cancer. 2005 Nov-Dec; 15(6):1035-41.
View in: PubMed

Campos S, Hamid O, Seiden MV, Oza A, Plante M, Potkul RK, Lenehan PF, Kaldjian EP, Varterasian ML, Jordan C, Charbonneau C, Hirte H. Multicenter, randomized phase II trial of oral CI-1033 for previously treated advanced ovarian cancer. J Clin Oncol. 2005 Aug 20; 23(24):5597-604.
View in: PubMed

Penson RT, Seiden MV, Matulonis UA, Appleman LJ, Fuller AF, Goodman A, Campos SM, Clark JW, Roche M, Eder JP. A phase I clinical trial of continual alternating etoposide and topotecan in refractory solid tumours. Br J Cancer. 2005 Jul 11; 93(1):54-9.
View in: PubMed

Gribben JG, Ryan DP, Boyajian R, Urban RG, Hedley ML, Beach K, Nealon P, Matulonis U, Campos S, Gilligan TD, Richardson PG, Marshall B, Neuberg D, Nadler LM. Unexpected association between induction of immunity to the universal tumor antigen CYP1B1 and response to next therapy. Clin Cancer Res. 2005 Jun 15; 11(12):4430-6.
View in: PubMed

Matulonis UA, Campos S, Krasner C, Duska L, Penson RP, Falke R, Roche M, Smith LM, Lee H, Seiden MV. A phase II trial of modified triple doublets for the treatment of advanced Müllerian malignancies. J Clin Oncol. 2005 Jun; 23(16_suppl):5010.
View in: PubMed

Vukelja S, O'Shaughnessy J, Campos S, Vahdat L, Blum J, Yardley D, Mainwaring P, Senecal F, Benner R, Denis L, Perez E. Activity of oral irinotecan (IRI) in metastatic breast cancer (MBC) patients after prior anthracycline, taxane and capecitabine: Phase 2 study results. J Clin Oncol. 2005 Jun; 23(16_suppl):562.
View in: PubMed

Lee CW, Matulonis UA, Campos SM, Gross AH, Hayes CM, Keenan KT, Castells MC. Rapid inpatient and outpatient desensitization for carboplatin or paclitaxel hypersensitivity: A protocol effective in patients with gynecologic malignancies. J Clin Oncol. 2005 Jun; 23(16_suppl):5090.
View in: PubMed

Penson RT, Krasner CN, Seiden MV, Atkinson T, Kornblith A, Campos S, Klein A, Matulonis U. Long-acting octreotide for the treatment of symptoms of bowel obstruction in advanced ovarian cancer. J Clin Oncol. 2005 Jun; 23(16_suppl):5159.
View in: PubMed

C.Lee, U.A.Matulonis, S.M.Campos, A.H.Gross, C.M.Hayes, K.T.Keenan, M.C.Castells, . Rapid inpatient and outpatient desensitization for carboplatin or paclitaxel hypersensitivity: a protocol effective in patients with gynecological malignancies. 2005; 23(ASCO 2005):A:5090.
View in: PubMed

R.T.Penson, C.N.Krasner, M.V.Seiden, T.Atkinson, S.M.Campos, A.Klein, U.Matulonis. Long-acting octreotide (Sandostatin LAR Depot) for the treatment of symptoms of bowel obstruction in advanced ovarian cancer. 2005; 23(ASCO 2005):A:5191.
View in: PubMed

S.Vukelija, J.O'Shaughnessy, S.M.Campos, L. Vahdat, J.Blum, D.Yardley, P.Mainwaring, F.Senecal, R.Benner, L.Denis, E.Perez. Activity of oral irinotecan (IRI) in metastatic breast cancer (MBC) patients after prior anthracycline, taxane and capecitabine: Phase 2 study results. 2005; 23(ASCO 2005):A:562.
View in: PubMed

Duska LR, Berkowitz R, Matulonis U, Muto M, Goodman A, McIntyre JF, Klein A, Atkinson T, Seiden MV, Campos S. A pilot trial of TAC (paclitaxel, doxorubicin, and carboplatin) chemotherapy with filgastrim (r-metHuG-CSF) support followed by radiotherapy in patients with "high-risk" endometrial cancer. Gynecol Oncol. 2005 Jan; 96(1):198-203.
View in: PubMed

U.A.Matulonis, S.M.Campos, C.Krasner, L.Duska, R.P.Penson, R.Falke, M.Roche, L.M.Smith, H.Lee, M.V.Seiden. A phase II trial of modified triple doublets for the treatment of advanced Mullerian malignancies. 2005; 23(ASCO 2005):A:5010.
View in: PubMed

Campos SM. Evolving treatment approaches for early breast cancer. Breast Cancer Res Treat. 2005; 89 Suppl 1:S1-7.
View in: PubMed

Thigpen JT, Aghajanian CA, Alberts DS, Campos SM, Gordon AN, Markman M, McMeekin DS, Monk BJ, Rose PG. Role of pegylated liposomal doxorubicin in ovarian cancer. Gynecol Oncol. 2005 Jan; 96(1):10-8.
View in: PubMed

Partridge EE, Abu-Rustum NR, Campos S, Edelson M, Fahey PJ, Fiorica J, Greer BE, Lieberman RW, Likes W, Molpus KL, Nava ME, Reynolds RK, Singh DK, Smith-McCune K, Soper J, Teng N, Trimble CL, Wilczynski S. Cervical cancer screening clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2004 Nov; 2(6):570-87.
View in: PubMed

Teng N, Abu-Rustum NR, Bahador A, Bookman MA, Bristow RE, Campos S, Cho KR, Copeland L, Eifel P, Fiorica J, Greer BE, Kapp DS, Kavanagh J, Koh WJ, Kuettel M, Lurain JR, Molpus KL, Nag S, Partridge EE, Powell CB, Reynolds RK, Small W, Soper J, Tillmanns TD. Cervical cancer guidelines. Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2004 Nov; 2(6):612-30.
View in: PubMed

Cameron DA, Winer E, Campos S, Guastalla JP. A comparative study of exemestane versus anastrozole in post-menopausal breast cancer subjects with visceral disease. J Clin Oncol. 2004 Jul 15; 22(14_suppl):628.
View in: PubMed

Campos SM, Seiden MV, Oza A, Plante M, Potkul R, Hamid O, Lenehan P, Kaldjian E, Jordan C, Hirte H. A phase 2, single agent study of CI-1033 administered at two doses in ovarian cancer patients who failed platinum therapy. J Clin Oncol. 2004 Jul 15; 22(14_suppl):5054.
View in: PubMed

Penson RT, Seiden MV, Campos SM, Krasner CN, Fuller AF, Goodman A, Roche M, Willman A, Muzikansky A, Matulonis UA. A phase II study of fixed dose-rate gemcitabine in patients with relapsed Müllerian tumors. J Clin Oncol. 2004 Jul 15; 22(14_suppl):5151.
View in: PubMed

Penson RT, Seiden MV, Goodman A, Fuller AF, Berkowitz RS, Matulonis UA, Krasner C, Lee H, Atkinson T, Campos SM. Phase I trial of escalating doses of topotecan in combination with a fixed dose of pegylated liposomal doxorubicin in women with müllerian malignancies. Gynecol Oncol. 2004 Jun; 93(3):702-7.
View in: PubMed

Campos SM. Aromatase inhibitors for breast cancer in postmenopausal women. Oncologist. 2004; 9(2):126-36.
View in: PubMed

R.T. Penson, M.V.Seiden, S.M.Campos, C.N.Krasner, A.F.Fuller, A.Goodman, M.Roche, A.Willman, A.Muzikansky, U.A.Matulonis; Massachusetts General Hospital, Boston,MA; Dana-Farber Cancer Institute, Boston,MA. A phase II study of fixed dose-rate gemcitabine in patients with relapsed Mullerian tumors. 2004; 22(ASCO 2004):A:5151.
View in: PubMed

D.A. Cameron, E.Winer, S.C.Campos, J.-P. Guastalla; Western General Hospital, Edinburgh, United Kingdom; Dana-Farber, Boston,MA; Centre Leon Berard, Lyon, France. A comparative study of exemestane versus anastroxole in post-metopausal breast cancer subjects aith visceral disease. 2004; 22(ASCO 2004):A:628.
View in: PubMed

S.M.Campos, M.V.Seiden, A.Oza, M.Plante, R.Potkul, O.Hamid, P.Lenehan, E.Kaldjian, C.Jordan, H.Hirte; Dana-Farber, Boston,MA; MAssachusetts General Hospital, Boston,MA; Princess Margaret, Toronto,ON, Canada; Pavilion L'Hotel-Dieu de Quebec, Quebec City, PQ, Canada; Loyola University Medical Center, Chicago IL; Pfizer, Inc, Ann Arbor, MI; Hamilton CAncer Center, Hamilton, ON, Canada. A phase 2, single agent study of CI-1033 administered at two doses in ovarian cancer patients who failed platinum therapy. 2004; 22(ASCO 2004):A:5054.
View in: PubMed

del Carmen MG, Fuller AF, Matulonis U, Horick NK, Goodman A, Duska LR, Penson R, Campos S, Roche M, Seiden MV. Phase II trial of anastrozole in women with asymptomatic müllerian cancer. Gynecol Oncol. 2003 Dec; 91(3):596-602.
View in: PubMed

Matulonis U, Campos S, Duska L, Fuller A, Berkowitz R, Gore S, Roche M, Colella T, Lee H, Seiden MV. A phase II trial of three sequential doublets for the treatment of advanced müllerian malignancies. Gynecol Oncol. 2003 Nov; 91(2):293-8.
View in: PubMed

Burstein HJ, Harris LN, Marcom PK, Lambert-Falls R, Havlin K, Overmoyer B, Friedlander RJ, Gargiulo J, Strenger R, Vogel CL, Ryan PD, Ellis MJ, Nunes RA, Bunnell CA, Campos SM, Hallor M, Gelman R, Winer EP. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. J Clin Oncol. 2003 Aug 01; 21(15):2889-95.
View in: PubMed

Campos S. Liposomal anthracyclines: adjuvant and neoadjuvant therapy for breast cancer. Oncologist. 2003; 8 Suppl 2:10-6.
View in: PubMed

Campos SM, Winer EP. Hormonal therapy in postmenopausal women with breast cancer. Oncology. 2003; 64(4):289-99.
View in: PubMed

U.MAtulonis, S.C.Campos, M.Seiden, C.Krasner, A.Fuller, L.Duska, R.Berkowitz, T.Collela, A.Crowe, A.Goodman; Dana-FArber CAncer Institute, Boston,MA; Massachusetts General Hospital, Boston,MA; Brigham and Women's Hospital, Boston,MA. Phase I study of cisplatin and gemcitabine for recurrent cervix cancer following primary radiotherapy or newly diagnosed metastatic cervix cancer. 2003; 22(ASCO 2003):A:1872.
View in: PubMed

S.M.Campos; Dana-Farber Cancer institute, Boston,MA. Epoetin alfa 40,000 u once weekly significantly improves hemoglobin and quality of life in anemic patients with ovarian cancer. 2003; 22(ASCO 2003):A:3111.
View in: PubMed

Seiden MV, Swenerton KD, Matulonis U, Campos S, Rose P, Batist G, Ette E, Garg V, Fuller A, Harding MW, Charpentier D. A phase II study of the MDR inhibitor biricodar (INCEL, VX-710) and paclitaxel in women with advanced ovarian cancer refractory to paclitaxel therapy. Gynecol Oncol. 2002 Sep; 86(3):302-10.
View in: PubMed

Campos S. The impact of anemia and its treatment on patients with gynecologic malignancies. Semin Oncol. 2002 Jun; 29(3 Suppl 8):7-12.
View in: PubMed

Vasey PA, Shulman LN, Campos S, Davis J, Gore M, Johnston S, Kirn DH, O'Neill V, Siddiqui N, Seiden MV, Kaye SB. Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus ONYX-015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer. J Clin Oncol. 2002 Mar 15; 20(6):1562-9.
View in: PubMed

H.J.Burstein, P.K.Marcom, R.Lambert-Falls, K.Havlin, B.Overmoyer, R.J.Friedlander, C.H.Weissman, R.Strenger, C.L.Vogel, P.D.Ryan, M.J.Ellis, L.N.Harris, C.A.Bunnell, S.M.Campos, M.Hallor, E.P.Winer, Dana-Farber Cancer Institute, Boston,MA; Duke University Medical Center, Durham,NC; South Carolina Oncology Associates, West Columbia,SC; Evanston,IL; University Hospitals of Cleveland, Cleveland,OH; New Hampshire Oncology-Hematology, Hooksett,NH; US Oncology, Latham,NY; Miriam Hospital, Providence, RI; Columbia Cancer Research Network, Plantation, FL; Massachusetts General Hospital, Boston,MA. Multicenter phase II study of trastuzumab (Herceptin;H) and vinorelbine (Navelbine;N) as first-line therapy for HER2 overexpressing metastic breast cancer (HER2+MBC). 2002; 21(ASCO 2002):A:211.
View in: PubMed

R.T.Penson, J.P.Eder, A.F.Fuller, J.G.Supko, U.Matulonis, S.M.Campos, L.J.Appleman, M.Roche, A.Harris, M.V.Seiden, Massachusetts General Hospital, Boston,MA; Dana-Farber Cancer Institute, Boston,MA. A phase I trial of continual sequential oral etoposide and infusional topotecan. 2002; 21(ASCO2002):A:2168.
View in: PubMed

M.Theodoulou, S.M.Campos, G.Batist, E.Winer, L.Norton, C.Hudis, L.Welles, Memorial Sloan-Kettering Cancer Center, New York,NY; Dana-Farber Cancer Institute, Boston,MA; Jewish General Hospital, McGill University, Montreal, QC, Canada; Elan Pharmaceuticals, Pinceton,NJ. TLC D99 (D,Myocet) Herceptin (H) is safe in advanced breast cancer (ABC): final cardiac safety and efficacy analysis. 2002; 21(ASCO 2002):A:216.
View in: PubMed

M.O.Butler, M.Seiden, M.Mihm, S.M.Campos, L.Duska, D.Goldstein, A.Goodman, D.Neuberg, N.Nikrui, U.Matulonis, M.Muto, R.Penson, I.Webb, A.Fuller, R.Berkowitz, L.Nadler, G.Dranoff, Dana-Farber Cancer Institute,Boston,MA; Massachuesetts General Hospital,Boston,MA; Brigham and Women's Hospital,Boston,MA. A phase I of vaccination with lethally irradiated, autologous ovarian cancer cells engineered by adenoviral mediated gene transfer to secrete human granulocyte-macrophage colony stimulating factor (GVAX). 2002; 21(ASCO 2002):A:1840.
View in: PubMed

Penson RT, Supko JG, Seiden MV, Fuller AF, Berkowitz RS, Goodman A, Campos SM, MacNeill KM, Cook S, Matulonis UA. A Phase I-II study of 96-hour infusional topotecan and paclitaxel for patients with recurrent Müllerian tumors. Cancer. 2001 Sep 01; 92(5):1156-67.
View in: PubMed

Burstein HJ, Kuter I, Campos SM, Gelman RS, Tribou L, Parker LM, Manola J, Younger J, Matulonis U, Bunnell CA, Partridge AH, Richardson PG, Clarke K, Shulman LN, Winer EP. Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2001 May 15; 19(10):2722-30.
View in: PubMed

Campos SM, Penson RT, Mays AR, Berkowitz RS, Fuller AF, Goodman A, Matulonis UA, Muzikansky A, Seiden MV. The clinical utility of liposomal doxorubicin in recurrent ovarian cancer. Gynecol Oncol. 2001 May; 81(2):206-12.
View in: PubMed

M.Theodoulou, S.M.Campos, L.Welles, G.Baptist, E.Winer, C.Hudis, Memorial Sloan-Kettering Cancer Center, New York,NY; Dana-Farber Cancer Institute, Boston,MA; The Liposome Company, Pinmceton, NJ; Jewish General Hospital (McGill Center for Translational Research), Montreal, Canada; Memorial-Sloan Kettering Cancer Center, New York, NY. Preliminary Cardiac Safety and Efficacy Data from Phase I/II Trial of TLC D-99 (D-99) and Trastuzumab (T) in patients withs locally advanced or Metastatic Breast CAncer (LABC/MBC). 2001; 20(ASCO 2001):A:180.
View in: PubMed

S.M.Campos, R.T.Penson, U.A.Matulonis, R.S.Berkowitz, L.D.Duska, A.F.Fuller, A.K.Goodman, N.Nikrui, E.E.Sheets, M.Muto, K.M.MacNeill, J.C.Sivert, M.Roche, K.Wilson, J.G.Supko, M.V.Seiden, Dana-Farber Cancer Institute, Boston,MA; Massachusetts General Hospital, Boston,MA. A Phase II and Pharmacokinetic/Dynamic study of Doxil and weekly Paclitaxel chemotherapy for Rucurrent Mullerian Tumors. 2001; 20(ASCO 2001):A:2524.
View in: PubMed

U.Matulonis, S.M.Campos, L.Duska, A.Fuller, R.Falke, S.Gore, R.Berkowitz, M.Roche, D.Finkelstein, J.Sivret, T.Colella, R.Penson, E.Sheets, M.Seiden, Dana-Farber/Partners Cancer Care, Boston,MA; Harvard Vanguard Medical Associates, Boston,MA. Triple Doublet Chemotherapy for the Treatment of Mullerian Malignancies. 2001; 20(ASCO 2001):A:846.
View in: PubMed

H.Burstein, I.Kuter, P.Richardson, S.M.CAmpos, L.Parker, U.Matulonis, L.Harris, J.GArber, J.Younger, C.Bunnell, L.Shulman, E.Winer. Herceptin and Vinorelbine for HER-2 Positive Metastatic Breast Cancer: A Phase II Study. 2000; 19(ASCO 2000):A:392.
View in: PubMed

C.Bunnell, L.Parker, U.Matulonis, L.Shulman, A.Elias, L.HArris, R. Scheib, H.Burstein, S.M.Campos, J.Younger, I.Kuter, E.Winer. A Phase I Study Cyclophosphamide, Doxorubicin, and Eniluracil/5-FU in Women with Advanced Breast Cancer: Preliminary Results. 2000; 19(ASCO 2000):A:444.
View in: PubMed

U.Matulonis, S.M.Campos, M.Seiden, A.Fuller, K.MacNeill, A.Charbonnier, R.Berkowitz, A.Goodman. Phase I Study Cisplatin and Gemcitabine for Recurrent Cervix Cancer Following Primary Radiotherapy. 2000; 19(ASCO 2000):A:1571.
View in: PubMed

A.Fuller, R.Penson, J.Supkp, U.Matulonis, R.Berkowitz, A.Goodman, S.Campos, K.MacNeill, K.Borden, S.Cook, S.Skates, M.Seiden. A Phase I/II Pharmacokinetic Study of 96-Hour Infusional Topotecan and Paclitaxel Chemotherapy for Recuurent Mullerian Tumors. 2000; 19(ASCO 2000):A:1552.
View in: PubMed

S.M.Campos, R.Penson, U.Matulonis, R.Berkowitz, L.Duska, A.Fuller, A.Goodman, N.Nikrui, E.Sheets, M.Muto, K.MacNeill, C.Genovese. A Phase II and Pharmacokinetic/Dynamic Studyof Doxil and Weekly Paclitaxel Chemotherapy for Recurrent Mullerian Tumors. 2000; 19(ASCO 2000):A:1623.
View in: PubMed

Botella-Estrada R, Sammartín O, Martínez V, Campos S, Aliaga A. Magnetic resonance angiography in the diagnosis of a case of giant cell arteritis manifesting as scalp necrosis. Arch Dermatol. 1999 Jul; 135(7):769-71.
View in: PubMed

S.M.Campos, R.Penson, K.MacNeill, R.Berkowitz, S.Cook, A.Fuller, A.Goodman, N.Najmosam, U.Matulonis, M.Seiden. A Retrospective Analysis of the Clinical Utility of Doxil in Recurrent Ovarian Cancer(ROC)(Meeting abstract). 1999; (ASCO 1999):A:1434.
View in: PubMed

Campos SM, Walden T. Images in clinical medicine. Spigelian hernia. N Engl J Med. 1997 Apr 17; 336(16):1149.
View in: PubMed

Location

Dana-Farber Cancer Institute
450 Brookline Avenue
Boston, MA 02215
Get Directions

Top